Eli Lilly and Company (LLY)
-NYSE 50.67 Oct 1, 4:00PM EDT|Pre-Market
:
50.67 0.00 (0.00%) 8:01AM EDT - Nasdaq Real Time Price
| Prev Close: | 50.67 |
|---|
| Open: | N/A |
|---|
| Bid: | 50.11 x 200 |
|---|
| Ask: | 50.70 x 200 |
|---|
| 1y Target Est: | 57.56 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 23-Oct-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 44.88 - 58.40 |
|---|
| Volume: | 308 |
|---|
| Avg Vol (3m): | 4,898,840 |
|---|
| Market Cap: | 54.73B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Healthcare Stocks Up as Obamacare Takes HoldWyatt Investment Research(Tue, Oct 1)
- These 2 Breast Cancer Treatment Makers Will Rise as Another Fallsat Motley Fool(Tue, Oct 1)
- Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic YearPR Newswire(Tue, Oct 1)
- 2014 Isn't Looking To Good For Eli Lilly And Companyat Seeking Alpha(Mon, Sep 30)
- Lilly mulls options as Medicare shuns Alzheimer's diagnosticReuters(Mon, Sep 30)
- Which Alzheimer's Fighter Will Benefit From a Boost in Federal Funding?at Motley Fool(Mon, Sep 30)
- Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013PR Newswire(Mon, Sep 30)
- Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid™ (Florbetapir F 18 Injection), Despite Support From Experts, Patients and the Alzheimer's Disease CommunityPR Newswire(Mon, Sep 30)
- Why This Health Care Giant Can Be a Core Holdingat Motley Fool(Sun, Sep 29)
- Cramer's Mad Money - 9 Things To Watch In The Week Ahead (9/27/13)at Seeking Alpha(Sun, Sep 29)
- This Week in Biotechat Motley Fool(Sat, Sep 28)
- Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid™ (Florbetapir F 18 Injection), Despite Support From Experts, Patients and the Alzheimer's Disease CommunityPR Newswire(Fri, Sep 27)
- Cramer's week ahead: DC heat melts market?at CNBC(Fri, Sep 27)
- Analyst Moves: LLY, MKC, MROat Forbes(Fri, Sep 27)
- A Phase III Failure At Eli Lilly - Yes, Againat Seeking Alpha(Fri, Sep 27)
Key Statistics
| Forward P/E (1 yr): | 18.29 |
|---|
| P/S (ttm): | 2.39 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 4.14 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 1.03 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | -3.29 |
|---|
Business Summary
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The companys neuroscience products treat major depressive disorders; schizophrenia, acute mixed or manic episodes associated with bipolar I...
View More